Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma
MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced that the first patient has been treated in the novel TRIDENT clinical trial, designed to demonstrate the OMNI® Surgical System with higher […]